MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$39,373K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of 2032 c...
Inducement expense
Proceeds from the sale and matur...
Others
Negative Cash Flow Breakdown
Repurchase of 2029 convertible s...
Purchase of marketable debt secu...
Net loss from continuing operati...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss from continuing operations
-34,797
-36,602
-21,986
25,706
Depreciation and amortization
4,234
25,212
18,137
15,788
Share based compensation
21,788
16,146
11,464
11,263
Foreign currency remeasurement impact
-3,416
-
-
301
In-process research and development
-
-
0
0
Loss on allowance for inventory
-
-
684
-
Amortization of debt discount and issuance costs
-
-
1,640
-
Amortization of discounts on investments
-
-
4,436
-
Inducement expense
40,008
-
-
-
Other
2,610
4
-43
807
Accounts receivable
-6,642
7,225
-27,819
44,155
Inventory
2,708
742
-1,177
-194
Income taxes
-
-
-849
-
Prepaid expenses and other current and non-current assets
3,075
6,382
-446
1,327
Change in lease assets and liabilities, net
-
-
-622
-
Accounts payable
-5,402
-11,809
6,247
-1,109
Accrued expenses
30,094
-20,900
17,339
19,701
Deferred revenue
0
0
0
0
Other current and non-current liabilities
2,947
1,940
-589
-10,636
Net cash provided by (used in) operating activities - continuing operations
-
-
60,678
14,317
Net cash (used in) provided by operating activities - discontinued operations
-
-
0
0
Net cash provided by (used in) operating activities
58,071
-40,366
60,678
14,317
Proceeds from the sale and maturity of marketable debt securities
36,367
48,782
82,420
106,622
Purchase of marketable debt securities
221,583
5,055
167,925
4,846
Purchase of fixed assets
-
-
-
140
Purchase of intangible assets
21,071
22,178
19,239
15,048
Payment of milestone
-
-
0
0
Other
0
0
470
-3
Net cash provided by (used in) investing activities - continuing operations
-
-
27,892
-
Net cash provided by investing activities - discontinued operations
-
-
0
-
Net cash (used in) provided by investing activities
-206,287
21,549
-104,839
86,591
Payment of guaranteed minimum royalty
525
525
525
525
Proceeds from issuance of 2032 convertible senior notes
525,000
-
-
-
Payment of debt issuance costs
16,270
-
-
-
Repurchase of 2029 convertible senior notes including premium
350,885
-
0
68,904
Proceeds from the issuance of common stock, net of issuance costs
-
-
0
-
Proceeds from the issuance of pre-funded warrants, net of issuance costs
-
-
0
-
Proceeds from exercise of stock options
27,841
4,729
25,949
4,090
Proceeds from issuances under the employee stock purchase plan
2,356
-
1,255
0
Net cash (used in) provided by financing activities - continuing operations
-
-
-33,467
-
Net cash used in financing activities - discontinued operations
-
-
0
-
Net cash provided by financing activities
187,517
4,204
26,679
-65,339
Effect of exchange rate changes on cash
72
-60
-413
207
Net increase in cash and cash equivalents
39,373
-14,673
-17,895
35,776
Cash and cash equivalents, beginning of year
78,362
93,035
110,930
58,535
Cash and cash equivalents, end of period
117,735
78,362
93,035
110,930
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
2032 convertible...
$525,000K
Inducement expense
$40,008K
Accrued expenses
$30,094K
(467.00%↑ Y/Y)
Proceeds from exercise of
stock options
$27,841K
(491.61%↑ Y/Y)
Proceeds from issuances
under the employee...
$2,356K
(53.29%↑ Y/Y)
Share based
compensation
$21,788K
(-1.59%↓ Y/Y)
Accounts receivable
-$6,642K
(-157.83%↓ Y/Y)
Depreciation and
amortization
$4,234K
(-84.21%↓ Y/Y)
Foreign currency
remeasurement impact
-$3,416K
(-257.78%↓ Y/Y)
Other current and
non-current liabilities
$2,947K
(93.25%↑ Y/Y)
Net cash provided by
financing activities
$187,517K
(3510.96%↑ Y/Y)
Net cash provided by
(used in) operating...
$58,071K
(256.06%↑ Y/Y)
Effect of exchange rate
changes on cash
$72K
(-97.12%↓ Y/Y)
Canceled cashflow
$367,680K
Canceled cashflow
$48,592K
Net increase in cash
and cash...
$39,373K
(136.92%↑ Y/Y)
Canceled cashflow
$206,287K
Repurchase of 2029
convertible senior notes...
$350,885K
Payment of debt issuance
costs
$16,270K
Payment of guaranteed
minimum royalty
$525K
(-50.00%↓ Y/Y)
Proceeds from the sale and
maturity of marketable...
$36,367K
(-72.97%↓ Y/Y)
Net loss from
continuing operations
-$34,797K
(35.54%↑ Y/Y)
Accounts payable
-$5,402K
(-3.43%↓ Y/Y)
Prepaid expenses and
other current and...
$3,075K
(-54.63%↓ Y/Y)
Inventory
$2,708K
(174.29%↑ Y/Y)
Other
$2,610K
(276.62%↑ Y/Y)
Net cash (used in)
provided by investing...
-$206,287K
(-547.09%↓ Y/Y)
Canceled cashflow
$36,367K
Purchase of marketable
debt securities
$221,583K
(244.23%↑ Y/Y)
Purchase of intangible
assets
$21,071K
(-11.73%↓ Y/Y)
Buy us a coffee
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)